REFERENCES
- Lalezari JP, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175–2185.
- Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186–2195.
- Lalezari J, Henry K, O'Hearn M, et al. Enfuvirtide (T-20) in combination with an optimized background (0B) regimen vs. OB alone: week 24 response among categories of treatment experience and baseline (BL) HIV antiretroviral (ARV) resistance. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Che-motherapy; September 27–30, 2002; San Diego, CA, USA. Abstract 3232.
- Lange J, Lazzarin A, Clotet B, et al. Enfuvirtide (T-20) in combination with an optimized background (0B) regimen vs. OB alone: week 24 response among categories of baseline (BL) demographics, treatment experience, and HIV anti-retroviral (ARV) resistance. In: Program and ab-stracts of the 6th International Congress on Drug Therapy in HIV Infection; November, 17–21, 2002; Glasgow, UK. Abstract PL14.3.
- Delfraissy J-F, Montaner J, Eron J, et al. Summary of pooled efficacy and safety analyses of enfuvirtide (ENF) treatment for 24 weeks in TORO 1 and TORO 2 Phase III trials in highly antiretroviTmral (ARV) treatment experienced patients. In: Program and abstracts of the 10th Conference on Retroviruses and Opportunistic Infections; February, 10–14, 2003; Boston, MA, USA. Abstract 568.
- Zhang X, Nieforth K, Lang J-M, et al. Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus: inverse Gaussian density absorption and 2-compartment disposi-tion. Clin Pharmacol Ther. 2002;72:10–19.
- Lalezari J, Eron J, Carlson M, et al. A Phase II clinical study (120-205) to determine the long-term safety and accept-ability of subcutaneously administered T-20 - an HIV fusion blocker. AIDS. 2003;17:691–698.
- Green J, Kleinman L, Ciesla G, et al. Subcutaneous Injec-tion Survey: psychometric evaluation of a treatment satis-faction instrument associated with a novel HIV medication. HIV Clin Trials. 2002;3:387–395.
- Cohen CJ, Dusek A, Green J, et al. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care STDs. 2002;16:327–335.
- Roche data on file.